ArticleNPJ precision oncology2026
Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real World Outcomes for the Efficacy and Safety of Osimertinib in Black Patients With Nonsmall Cell Lung Cancer.Clinical lung cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osimertinib has been one of the most commonly prescribed first-line treatments for EGFR-mutated advanced NSCLC for the last several years for patients with EGFR-mutated non-small cell lung cancer (NSCLC), yet clinical outcomes among racial and ethnic minority patients remain poorly characterized due to underrepresentation in pivotal trials. We conducted a retrospective study of 174 patients with advanced EGFR-mutated NSCLC treated at the Montefiore Einstein Comprehensive Cancer Center (MECCC) from 2015 to 2024 to evaluate real-world survival and treatment adherence. The cohort included 32.2% Hispanic, 28.7% non-Hispanic Black (NHB), 26.4% non-Hispanic White (NHW), and 12.6% Asian patients. In multivariable analyses, NHB patients experienced significantly worse overall survival compared with NHW patients, both in the overall cohort (Hazard ratio (HR) 1.83, 95% confidence interval (CI) 1.02-3.27) and in first-line osimertinib users (HR 3.42, 95% CI 1.48-7.88), despite similar adherence rates. Hispanic and Asian patients also showed trends toward inferior outcomes. These findings highlight survival disparities and underscore the need for inclusive trials and targeted strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.